Tau PROGRAM（AnHorn Medicines）

N/A

Report date: 2022/12/16 17:04:25
NME

Base Information

Drug NameTau PROGRAM（AnHorn Medicines）
Drug Alias NameN/A
ClassificationSmall molecules > Proteolysis-Targeting Chimera (PROTAC)
Mechanisms of ActionMicrotubule-associated protein tau degraders
TargetsMicrotubule-associated protein tau
Therapy Area/IndicationsFrontotemporal DementiaAlzheimer DiseaseSupranuclear Palsy, Progressive
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryTaiwan
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesAnHorn Medicines Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesAnHorn Medicines Co Ltd
Inactive CompaniesN/A
Active IndicationsFrontotemporal DementiaAlzheimer DiseaseSupranuclear Palsy, Progressive
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A